Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJQDUC)

• Drug Name: Aminoguanidine Drug Info
• Synonyms: aminoguanidine; Pimagedine; Hydrazinecarboximidamide; Guanyl hydrazine; Monoaminoguanidine; 2-aminoguanidine; 79-17-4; Imino semicarbazide; Aminate base; 2-azanylguanidine; Pimagedine [INN]; GUANIDINE, AMINO-; 1-aminoguanidine; UNII-SCQ4EZQ113; Hydrazinecarboximidamide(9CI); CCRIS 3511; EINECS 201-183-1; Aminoguanidine, Hemisulfate; SCQ4EZQ113; CHEMBL225304; CHEBI:40618; HAMNKKUPIHEESI-UHFFFAOYSA-N; guanylhydrazine; GER-11; AGU; amino guanidine; 1-amino-guanidine; Aminoguanidine (AG); Tocris-0787; Carbonohydrazonic diamide; INCB3284

Indication

Disease Entry	ICD 11	Status	REF
Diabetic retinopathy	9B71.0	Phase 1	[1]
Insulin-resistant disorder	5A44	Discontinued in Phase 2	[2]
Rheumatoid arthritis	FA20	Discontinued in Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 2146
  ChEBI ID: CHEBI:40618
  CAS Number: CAS 79-17-4
  TTD Drug ID: DMJQDUC

Molecule-Related Drug Atlas

Drug(s) Targeting Nitric-oxide synthase inducible (NOS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[5]
SD-6010	DM9DEYL	Osteoarthritis	FA00-FA05	Phase 3	[6]
MPL-S	DMNDCFY	Endotoxic shock	1G41	Phase 3	[7]
Pimagedine HCl	DMPWH30	Diabetic kidney disease	GB61.Z	Phase 2/3	[8]
GW274150	DMZMCB1	Asthma	CA23	Phase 2	[9]
BXT-51072	DMD8GNB	Cardiovascular disease	BA00-BE2Z	Phase 2	[10]
HP-228	DMNZ35F	Postoperative pain	MG30-MG3Z	Phase 2	[11]
CR-3294	DMHJEZS	Diarrhea	ME05.1	Phase 2	[12]
KD-7040	DME1WV2	Pain	MG30-MG3Z	Phase 2	[13]
LT-1951	DM5N04G	Coronary artery disease	BA80	Phase 1/2	[14]

Drug(s) Targeting C-C chemokine receptor type 2 (CCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cenicriviroc	DM4V8WF	Human immunodeficiency virus infection	1C62	Phase 2	[15]
MLN1202	DM24SOL	Metastatic cancer	2D50-2E2Z	Phase 2	[16]
BMS-813160	DMKY638	Diabetic nephropathy	GB61.Z	Phase 2	[17]
CCX-140	DMJ9XCO	Diabetic nephropathy	GB61.Z	Phase 2	[18]
AZD-2423	DMF34UY	Chronic obstructive pulmonary disease	CA22	Phase 2	[19]
CCX872	DMPVAUT	Pancreatic tumour	2C10	Phase 2	[20]
MK-0812	DMRT8K4	Multiple sclerosis	8A40	Phase 2	[21]
TAK-202	DMVYEFZ	Melanoma	2C30	Phase 1	[22]
OPL-CCL2-LPM	DM3HOUX	Arthritis	FA20	Phase 1	[23]
CNTX-6970	DMCOJM7	Inflammatory pain	MG30.42	Phase 1	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 2 (CCR2)	TTFZYTO	CCR2_HUMAN	Antagonist	[3]
Nitric-oxide synthase inducible (NOS2)	TTF10I9	NOS2_HUMAN	Inhibitor	[4]

References

• [1] ClinicalTrials.gov (NCT02099981) Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients in University of Minnesota - Clinical and Translational Science Institute.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018258)
• [3] Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
• [4] Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800.
• [5] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [6] A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
• [7] Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
• [8] Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
• [9] GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
• [10] Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
• [11] HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
• [12] Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
• [13] WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
• [14] Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [17] A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
• [18] Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
• [19] CA patent application no. 841416, Method of selecting therapeutic indications.
• [20] Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
• [21] Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303.
• [24] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)